• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low-dose dasatinib: when less can be more.

作者信息

Amrein Philip Crawford

机构信息

Massachusetts General Hospital, Boston, MA, USA.

出版信息

Lancet Haematol. 2021 Dec;8(12):e867-e868. doi: 10.1016/S2352-3026(21)00342-2.

DOI:10.1016/S2352-3026(21)00342-2
PMID:34826406
Abstract
摘要

相似文献

1
Low-dose dasatinib: when less can be more.低剂量达沙替尼：少即是多。
Lancet Haematol. 2021 Dec;8(12):e867-e868. doi: 10.1016/S2352-3026(21)00342-2.
2
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.达沙替尼：从治疗对伊马替尼耐药或不耐受的慢性髓性白血病患者到治疗新诊断的慢性期慢性髓性白血病患者。
Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27.
3
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.新型慢性髓性白血病初诊患者每日接受低剂量达沙替尼（50mg）治疗的长期随访结果。
Cancer. 2020 Jan 1;126(1):67-75. doi: 10.1002/cncr.32504. Epub 2019 Sep 25.
4
Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
Cancer. 2018 Nov 1;124(21):4260-4261. doi: 10.1002/cncr.31682. Epub 2018 Oct 1.
5
Reply to Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
Cancer. 2018 Nov 1;124(21):4261. doi: 10.1002/cncr.31683. Epub 2018 Oct 1.
6
Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.一线达沙替尼治疗新诊断慢性期慢性髓性白血病的临床疗效与安全性以及BCR-ABL1转录本下降速度与实现分子反应的相关性：顺天堂山梨合作研究组报告
Oncology. 2018;94(2):85-91. doi: 10.1159/000481945. Epub 2017 Nov 18.
7
The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group.低剂量达沙替尼作为慢性期慢性髓性白血病患者后续治疗的疗效：关东慢性髓性白血病研究组的LD-CML研究
Intern Med. 2018 Jan 1;57(1):17-23. doi: 10.2169/internalmedicine.9035-17. Epub 2017 Oct 16.
8
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
9
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.达沙替尼可使对伊马替尼耐药或不耐受的慢性期慢性髓性白血病患者产生持久的细胞遗传学反应。
Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10.
10
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study.达沙替尼联合纳武单抗用于既往治疗过的慢性髓性白血病患者的安全性和疗效：1b期剂量递增研究结果
Leuk Lymphoma. 2021 Aug;62(8):2040-2043. doi: 10.1080/10428194.2021.1889536. Epub 2021 Mar 2.

引用本文的文献

1
Dasatinib Dose Optimization Based on Therapeutic Drug Monitoring in Patients with Chronic-Phase Chronic Myeloid Leukemia.基于治疗药物监测的达沙替尼剂量优化在慢性期慢性髓性白血病患者中的应用
Drug Des Devel Ther. 2025 May 23;19:4311-4320. doi: 10.2147/DDDT.S521260. eCollection 2025.